Want to see XLO full AI Analyst Report?
Xilio Therapeutics (XLO) Income Statement
Xilio Therapeutics Income Statement
Last quarter (Q2 2026), Xilio Therapeutics's total revenue was $18.69M, an increase of 131.22% from the same quarter last year. In Q2, Xilio Therapeutics's net income was $-6.37M. See Xilio Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 43.77M | $ 6.34M | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 42.23M | $ 6.34M | $ 0.00 | $ 0.00 | $ -1.50M | |
| $ 84.21M | $ 66.93M | $ 79.13M | $ 89.15M | $ 73.55M | |
| Depreciation and Amortization | $ 1.54M | $ 1.64M | $ 1.90M | $ 1.85M | $ 1.50M |
| $ -33.49M | $ -58.00M | $ -74.50M | $ -86.38M | $ -73.70M | |
| $ -41.98M | $ -60.58M | $ -79.13M | $ -89.15M | $ -75.04M | |
| $ 6.95M | $ 2.34M | $ 2.73M | $ 927.00K | $ -756.00K | |
| $ -35.04M | $ -58.24M | $ -76.40M | $ -88.22M | $ -75.80M | |
| $ -35.04M | $ -58.24M | $ -76.40M | $ -88.22M | $ -75.80M | |
| Per Share Metrics | |||||
| Basic EPS | $ -4.19 | $ -15.26 | $ -38.92 | $ -45.08 | $ -189.28 |
| Diluted EPS | $ -4.19 | $ -15.26 | $ -38.92 | $ -45.08 | $ -189.28 |
| Weighted Average Shares Outstanding | 8.36M | 3.82M | 1.96M | 1.96M | 400.45K |
| Weighted Average Shares Outstanding (Diluted) | 8.36M | 3.82M | 1.96M | 1.96M | 400.45K |
Currency in USD